SG11202102143RA - Crystalline (r)-5-carbamoylpyridin-3-yl-2-methyl-4-(3-(trifluoromethoxy)benzyl) piperazine-1-carboxylate, compositions and methods of use thereof - Google Patents

Crystalline (r)-5-carbamoylpyridin-3-yl-2-methyl-4-(3-(trifluoromethoxy)benzyl) piperazine-1-carboxylate, compositions and methods of use thereof

Info

Publication number
SG11202102143RA
SG11202102143RA SG11202102143RA SG11202102143RA SG11202102143RA SG 11202102143R A SG11202102143R A SG 11202102143RA SG 11202102143R A SG11202102143R A SG 11202102143RA SG 11202102143R A SG11202102143R A SG 11202102143RA SG 11202102143R A SG11202102143R A SG 11202102143RA
Authority
SG
Singapore
Prior art keywords
carbamoylpyridin
trifluoromethoxy
piperazine
carboxylate
benzyl
Prior art date
Application number
SG11202102143RA
Inventor
Lianfeng Huang
Nancy Tsou
Nicole White
Jun Xu
Qun Zhang
Original Assignee
Celgene Corp
Abide Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp, Abide Therapeutics Inc filed Critical Celgene Corp
Publication of SG11202102143RA publication Critical patent/SG11202102143RA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/94Oxygen atom, e.g. piperidine N-oxide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
SG11202102143RA 2018-09-13 2019-09-12 Crystalline (r)-5-carbamoylpyridin-3-yl-2-methyl-4-(3-(trifluoromethoxy)benzyl) piperazine-1-carboxylate, compositions and methods of use thereof SG11202102143RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862731014P 2018-09-13 2018-09-13
PCT/US2019/050771 WO2020056105A1 (en) 2018-09-13 2019-09-12 Crystalline (r)-5-carbamoylpyridin-3-yl-2-methyl-4-(3-(trifluoromethoxy)benzyl) piperazine-1-carboxylate, compositions and methods of use thereof

Publications (1)

Publication Number Publication Date
SG11202102143RA true SG11202102143RA (en) 2021-04-29

Family

ID=68069873

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202102143RA SG11202102143RA (en) 2018-09-13 2019-09-12 Crystalline (r)-5-carbamoylpyridin-3-yl-2-methyl-4-(3-(trifluoromethoxy)benzyl) piperazine-1-carboxylate, compositions and methods of use thereof

Country Status (21)

Country Link
US (3) US11053199B2 (en)
EP (2) EP3849970B1 (en)
JP (1) JP7405840B2 (en)
KR (1) KR20210057789A (en)
CN (3) CN118561814A (en)
AU (1) AU2019337623A1 (en)
BR (1) BR112021004340A2 (en)
CA (1) CA3112200A1 (en)
CL (1) CL2021000596A1 (en)
CO (1) CO2021003295A2 (en)
DK (1) DK3849970T3 (en)
EA (1) EA202190511A1 (en)
FI (1) FI3849970T3 (en)
IL (1) IL281276B1 (en)
LT (1) LT3849970T (en)
MA (1) MA53607A (en)
MX (1) MX2021002923A (en)
PT (1) PT3849970T (en)
RS (1) RS65967B1 (en)
SG (1) SG11202102143RA (en)
WO (1) WO2020056105A1 (en)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007010076A (en) * 2005-02-17 2007-10-16 Astellas Pharma Inc Pyridyl non-aromatic nitrogenated heterocyclic-1-carboxylate ester derivative.
EP3099332A4 (en) * 2014-01-29 2017-06-21 Madrigal Pharmaceuticals, Inc. Targeted therapeutics
NZ756915A (en) 2017-03-13 2023-03-31 Lundbeck La Jolla Research Center Inc Dual magl and faah inhibitors

Also Published As

Publication number Publication date
US20210363105A1 (en) 2021-11-25
US11680046B2 (en) 2023-06-20
DK3849970T3 (en) 2024-09-30
JP7405840B2 (en) 2023-12-26
EP4434583A2 (en) 2024-09-25
WO2020056105A9 (en) 2020-07-09
IL281276A (en) 2021-04-29
JP2022500441A (en) 2022-01-04
CN113227069A (en) 2021-08-06
KR20210057789A (en) 2021-05-21
EA202190511A1 (en) 2021-07-05
CN118530218A (en) 2024-08-23
CN113227069B (en) 2024-11-05
PT3849970T (en) 2024-09-25
BR112021004340A2 (en) 2021-05-25
US20200095201A1 (en) 2020-03-26
EP3849970A1 (en) 2021-07-21
US20230382861A1 (en) 2023-11-30
US11053199B2 (en) 2021-07-06
MX2021002923A (en) 2021-09-08
IL281276B1 (en) 2024-09-01
EP3849970B1 (en) 2024-07-03
CL2021000596A1 (en) 2021-07-30
RS65967B1 (en) 2024-10-31
FI3849970T3 (en) 2024-09-20
AU2019337623A1 (en) 2021-05-13
MA53607A (en) 2021-12-22
CA3112200A1 (en) 2020-03-19
CO2021003295A2 (en) 2021-07-30
LT3849970T (en) 2024-10-10
WO2020056105A1 (en) 2020-03-19
CN118561814A (en) 2024-08-30

Similar Documents

Publication Publication Date Title
IL288104A (en) Heterocyclic compounds, preparation methods and uses thereof
IL288278A (en) Substituted 1-oxo-isoindoline-5-carboxamide compounds, compositions thereof, and methods of treatment therewith
IL274488A (en) Crystalline forms of n-(4-(4-(cyclopropylmethyl) piperazine-1-carbonyl)phenyl)quinoline-8-sulfonamide
EP3846639A4 (en) Antipathogenic compositions and methods thereof
IL285302A (en) Compounds, compositions and methods
IL283968A (en) Benzamides of pyrazolyl-amino-pyrimidinyl derivatives, and compositions and methods thereof
IL280809B (en) Novel compositions, their use, and methods for their formation
EP3697791A4 (en) Heterocyclic compounds, compositions comprising heterocyclic compound, and methods of use thereof
IL282939A (en) Mixtures and compositions comprising 5-fluoro-4-imino-3- methyl-1-tosyl-3,4- dihydropyrimidin-2-one, and methods of use thereof
IL277786A (en) Aav compositions, methods of making and methods of use
EP3411046A4 (en) Rapaglutins, novel inhibitors of glut and use thereof
IL287262A (en) Methods and compositions for transgene expression
SG11202011227VA (en) Compositions comprising bisfluoroalkyl-1,4-benzodiazepinone compounds and methods of use thereof
IL287120A (en) Compounds, compositions and methods
IL287014A (en) Benzethers and anilines of pyrazolyl-amino-pyrimidinyl derivatives, and compositions and methods thereof
IL286164A (en) Novel 3-(2-bromo-4-alkynyl-6-alkoxyphenyl)-3-pyrrolin-2-ones and their use as herbicides
EP3747870A4 (en) Pyridazinol compound, derivative thereof, preparation method therefor, herbicidal composition and use thereof
EP3845538A4 (en) Dihydroimidazopyrazinone compound, composition including same, and use thereof
EP3836938A4 (en) Solid forms of substituted benzoxaborole and compositions thereof
EP3773711A4 (en) Irradiation-inactivated poliovirus, compositions including the same, and methods of preparation
IL281276A (en) Crystalline (r)-5-carbamoylpyridin-3-yl-2-methyl-4-(3-(trifluoromethoxy)benzyl) piperazine-1-carboxylate, compositions and methods of use thereof
EP3599853A4 (en) Herbicidal compositions and methods of use thereof
EP3801589A4 (en) Methods and compositions for the treatment of osteopetrosis
EP3749354A4 (en) Novel composition and use thereof
IL286325A (en) Specifically substituted 3-(2-alkoxy-6-alkyl-4-propinylphenyl)-3-pyrrolin-2-ones and their use as herbicides